Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis
NCT ID: NCT00440661
Last Updated: 2010-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
96 participants
INTERVENTIONAL
2007-03-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Symptomatic Efficacy of Diacerein in Knee Osteoarthritis
NCT00445276
Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee
NCT00722852
Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)
NCT01967550
Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
NCT00426621
Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip
NCT00451360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diacerhein
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hydarthrosis (synovial effusion)
Exclusion Criteria
* severe pathologies
* anti-osteoarthritic treatments
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoires NEGMA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Negma-Lerads
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Pierre RAYNAULD, MD
Role: PRINCIPAL_INVESTIGATOR
Institut de Rhumatologie de Montreal
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheumatologic Institut of Montreal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
109196
Identifier Type: -
Identifier Source: secondary_id
HEC/ART06572N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.